Immuron Limited American Depositary Shares (IMRN)

FairStock Score: 45/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach Immuron as a tiny, loss-making biopharmaceutical concern, not as a mature business. The company sells Travelan, an over-the-counter product for travelers' diarrhea, and pursues polyclonal antibodies, but it has only seven employees and a $7.3 million market capitalization. That scale gives it little room for error. On the numbers supplied, the stock closed at $1.04 on 2026-10-13, with a FairStock P/E of -2.81 and a P/B of 1.07. The negative multiple means there are no positive earnings to value; book value is the main anchor. Return on equity is -40.25% and return on capital employed is -21.68%, both FairStock calculations. Debt is modest, with D/E at 0.02, but low leverage does not offset continuing losses. The Piotroski F-Score of 1/9 and Altman Z-Score of -4.55 point to weak financial health and possible distress. The 52-week range of $0.68 to $2.39 shows how volatile the shares have been; beta is 0.52. Revenue growth and profit growth are not available, and the Lynch category is none because there are only 0 years of filed results and the rules need 3. A Graham-style investor would ask for a margin of safety. At 1.07 times book, the price is not obviously expensive versus assets, but losses can erode that book value quickly. Without evidence of durable earnings power, a moat, or a multi-year track record, this remains speculative. The 45/100 FairStock score summarizes that mediocre picture.

In plain English: Immuron is a very small biopharmaceutical company that sells Travelan, an over-the-counter product for travelers' diarrhea, and researches antibody treatments. The business looks weak today: it is losing money, has only seven employees, and several financial-health signs are poor. At $1.04, the shares are not clearly cheap because there are no profits; they trade near their accounting value, so the price looks roughly fair but very speculative.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer